Isothermal Nucleic Acid Amplification Technology (INAAT) Market Report 2026

The isothermal nucleic acid amplification technology (inaat) market size has grown rapidly in recent years. It will grow from $4.33 billion in 2025 to $4.95 billion in 2026 at a compound annual growth rate (CAGR) of 14.3%. The growth in the historic period can be attributed to increasing prevalence of infectious diseases, rising demand for rapid diagnostic techniques, limitations of traditional pcr methods, growing use of molecular diagnostics in hospitals, expansion of blood screening programs.

The isothermal nucleic acid amplification technology (inaat) market size is expected to see rapid growth in the next few years. It will grow to $8.57 billion in 2030 at a compound annual growth rate (CAGR) of 14.7%. The growth in the forecast period can be attributed to growth in decentralized diagnostic testing, rising adoption of portable diagnostic instruments, increasing focus on early disease detection, expanding applications in oncology diagnostics, rising healthcare investments in emerging markets. Major trends in the forecast period include rapid point-of-care molecular testing adoption, growing demand for portable inaat instruments, expansion of isothermal amplification in infectious disease testing, increased use of inaat in blood screening programs, rising preference for fast and low-complexity diagnostic workflows.

The rising prevalence of infectious and chronic diseases is fueling the growth of the Isothermal Nucleic Acid Amplification Technology (INAAT) market. The occurrence of infectious diseases such as H. influenzae and S. pneumoniae (respiratory tract infections), N. gonorrhoeae and C. trachomatis (genital infections), and tuberculosis (TB) is increasing, creating a demand for isothermal nucleic acid amplification technology (INAAT) for accurate diagnosis. For example, in 2023, according to the World Health Organization (WHO), a Switzerland-based health organization, an estimated 10 million people are infected with tuberculosis annually, and 1.5 million people die from this infectious disease. The rise in infectious and chronic diseases drives the expansion of the isothermal nucleic acid amplification technology market.

Major companies operating in the isothermal nucleic acid amplification technology market are creating innovative solutions such as the QIAstat-Dx syndromic testing solution to strengthen their market position. The QIAstat-Dx system is a fully integrated, multiplexed molecular testing platform that combines sample preparation, nucleic acid amplification, and detection within a single cartridge. For example, in April 2023, Qiagen, a Netherlands-based company that develops isothermal nucleic acid amplification technology (INAAT) for various applications, launched the QIAstat-Dx syndromic testing solution. The system provides Ct (cycle threshold) values and convenient access to amplification curves, enabling clinicians to monitor the amplification process and make well-informed diagnostic decisions.

In February 2023, Sherlock Biosciences, a U.S.-based biotechnology company, acquired Sense Biodetection for an undisclosed amount. Through this acquisition, Sherlock aims to strengthen its diagnostic capabilities by combining Sense's LAMP-based technology with its own advanced CRISPR methods, enhancing the speed and accessibility of molecular testing. Sense Biodetection, a UK-based company, specializes in developing rapid, point-of-care diagnostic solutions that utilize isothermal nucleic acid amplification technologies, particularly Loop-Mediated Isothermal Amplification (LAMP).

Major companies operating in the isothermal nucleic acid amplification technology (inaat) market are Abbott Laboratories, bioMérieux SA, Qiagen NV, Becton, Dickinson and Company, Hologic Inc., Quidel Corporation, Thermo Fisher Scientific Inc., New England Biolabs Inc., Lucigen Corporation, BioHelix Corporation, Meridian Bioscience Inc., Ustar Biotechnologies Ltd., Atila Biosystems Incorporated, OptiGene Limited, DiaSorin SpA, Grifols SA, LGC Ltd., Jena Bioscience GmbH, Eiken Chemical Co., Ltd., Canon Medical Systems Corporation, Roche Diagnostics International AG.

North America was the largest region in the isothermal nucleic acid amplification technology (INAAT) market in 2025. Western Europe was the second largest region in the isothermal nucleic acid amplification technology (INAAT) market. The regions covered in the isothermal nucleic acid amplification technology (inaat) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the isothermal nucleic acid amplification technology (inaat) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have moderately impacted the isothermal nucleic acid amplification technology market by increasing the cost of imported instruments, enzymes, and specialized reagents used in molecular diagnostics. Reagent and instrument segments are most affected, particularly in Asia-pacific and north America where cross-border sourcing and manufacturing dependencies are high. However, tariffs have also encouraged regional production of diagnostic reagents and instruments, improved supply chain localization, and supported innovation in cost-efficient inaat platforms for domestic markets.

The isothermal nucleic acid amplification technology (inaat) market research report is one of a series of new reports that provides isothermal nucleic acid amplification technology (inaat) market statistics, including isothermal nucleic acid amplification technology (inaat) industry global market size, regional shares, competitors with a isothermal nucleic acid amplification technology (inaat) market share, detailed isothermal nucleic acid amplification technology (inaat) market segments, market trends and opportunities, and any further data you may need to thrive in the isothermal nucleic acid amplification technology (inaat) industry. This isothermal nucleic acid amplification technology (inaat) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Isothermal nucleic acid amplification technology (INAAT) is a method that amplifies DNA samples. This technology is used to amplify DNA sequences from two distinct nucleic acid segments at a constant temperature.

The primary product types of isothermal nucleic acid amplification technology are instruments and reagents. A reagent is a substance or compound added to a system to trigger a chemical reaction or to detect whether a reaction has occurred. The different technologies employed include NASBA and HAD, which are utilized for blood screening, infectious disease diagnostics, and cancer. The various end users include hospitals, reference laboratories, and other facilities.

The isothermal nucleic acid amplification technology (INAAT) market includes revenues earned by reaction systems and related services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.